08048036315
VIVITRA 150MG Injection wholesale and global supplier from India to Australia | Phoenix Exim.

1. General Information

VIVITRA 150MG Injection is an anti-neoplastic medicine containing trastuzumab. Trastuzumab belongs to the monoclonal-antibody class and specifically targets the HER2 protein, which may be overexpressed on certain cancer cells.

Because this medicine can cause potentially serious cardiac, pulmonary, and infusion-related reactions, treatment should be prescribed and monitored by an experienced healthcare professional.

2. Product Information

  • Brand: VIVITRA 150MG Injection
  • Active ingredient: Trastuzumab
  • Strength: 150 mg
  • Dosage form: Injection
  • Therapeutic class: Antineoplastic / targeted cancer therapy
  • Drug class: Monoclonal antibody
  • Route: Intravenous infusion
  • Manufacturer/marketer: Zydus
  • Primary target: HER2 (Human Epidermal Growth Factor Receptor 2)
  • Storage: Typically refrigerated at 2°C–8°C, according to the applicable product labeling.

3. Uses of VIVITRA 150MG Injection

VIVITRA is used for cancers in which testing confirms HER2 positivity.

HER2-positive breast cancer

It may be used in different treatment settings, including early-stage and metastatic HER2-positive breast cancer, either alone or with other anti-cancer medicines depending on the treatment plan.

HER2-positive gastric cancer

Trastuzumab may also be used with chemotherapy for appropriate patients with advanced or metastatic HER2-positive gastric or gastroesophageal-junction cancer.

4. Benefits of This Medicine

The principal benefit of trastuzumab is its targeted action against HER2-positive cancer cells.

Potential therapeutic benefits include:

  • Helps inhibit HER2-mediated cancer-cell growth.
  • Helps slow the progression of HER2-positive cancers.
  • Can improve treatment outcomes when appropriately combined with other cancer therapies.
  • Provides a targeted treatment approach rather than acting through a nonspecific mechanism alone.
  • May help the immune system recognize and attack HER2-expressing cancer cells.

The actual benefit depends on the cancer type, stage, HER2 status, previous treatments, and the patient's overall health.

5. Side Effects of VIVITRA 150MG Injection

Possible adverse effects include:

  • Infusion-related reactions
  • Fever and chills
  • Headache
  • Nausea or vomiting
  • Diarrhea
  • Fatigue or weakness
  • Cough
  • Rash
  • Muscle or joint pain
  • Injection/infusion-site reactions

More serious reactions can include heart problems, severe hypersensitivity reactions, and pulmonary toxicity.

6. Common Side Effects

Some commonly reported effects include:

  1. Fever or chills
  2. Headache
  3. Nausea
  4. Vomiting
  5. Diarrhea
  6. Cough
  7. Fatigue
  8. Muscle or joint pain
  9. Rash
  10. Sleep disturbances

Patients should tell their healthcare provider if side effects are persistent, severe, or worsening.

7. How to Use VIVITRA 150MG Injection

VIVITRA should not be self-administered. It is given as an intravenous infusion by a qualified healthcare professional in an appropriate medical setting.

The dosage and treatment schedule are individualized according to the patient's diagnosis and treatment protocol. Trastuzumab dosing is commonly weight-based, and different approved regimens may be used depending on the indication.

The healthcare team may monitor vital signs and observe the patient for infusion reactions during and after administration. Cardiac function may also be assessed during treatment.

8. How This Medicine Works

VIVITRA contains trastuzumab, which binds to the HER2 receptor on the surface of HER2-positive cancer cells.

This targeted binding can:

  • Block HER2 signaling involved in cancer-cell growth.
  • Reduce signals that support cancer-cell survival and proliferation.
  • Promote immune-mediated destruction of HER2-expressing cells.

Together, these mechanisms can help slow the growth and progression of HER2-positive cancer.

9. Safety Advice

Prescription use: Use only under the supervision of an oncologist or qualified healthcare professional.

Heart conditions: Tell your doctor about previous heart disease, reduced heart function, hypertension, or other cardiovascular problems because trastuzumab can cause cardiac complications.

Lung problems: Inform your doctor about existing respiratory conditions. Seek urgent medical attention for significant breathing difficulties or persistent respiratory symptoms.

Pregnancy: Trastuzumab can cause fetal harm. Patients who are pregnant or may become pregnant should discuss the risks and appropriate contraception with their healthcare professional.

Breastfeeding: Discuss breastfeeding with your physician before starting treatment.

Allergy/infusion reaction: Immediate medical attention is required for severe breathing difficulty, swelling, severe rash, chest discomfort, or other symptoms of a serious infusion reaction.

Storage: Follow the product-specific storage instructions and maintain the required cold chain. Do not use the medicine if its packaging or storage conditions have been compromised.

10. FAQs

Q1. What is VIVITRA 150MG Injection?

VIVITRA 150MG Injection contains trastuzumab, a targeted monoclonal antibody used for certain HER2-positive cancers.

Q2. What is VIVITRA 150MG used for?

It is used primarily for HER2-positive breast cancer and, in appropriate treatment protocols, HER2-positive gastric/gastroesophageal-junction cancer.

Q3. Is VIVITRA a chemotherapy medicine?

It is an anti-cancer targeted therapy rather than a traditional cytotoxic chemotherapy. It is sometimes administered alongside chemotherapy as part of a cancer treatment regimen.

Q4. How is VIVITRA administered?

It is administered by intravenous infusion by a qualified healthcare professional.

Q5. Can I inject VIVITRA myself?

No. VIVITRA should not be self-administered.

Q6. Does VIVITRA require refrigeration?

Yes. Product-specific instructions generally require refrigerated storage, commonly 2°C–8°C. Always follow the manufacturer's approved labeling.

Q7. What is the active ingredient in VIVITRA?

The active ingredient is trastuzumab 150 mg.

Q8. Can VIVITRA cause heart problems?

Yes. Trastuzumab treatment can cause cardiac dysfunction, so appropriate cardiac monitoring may be required during therapy.

Q9. Can VIVITRA be used for every breast cancer patient?

No. It is specifically intended for appropriate HER2-positive cancers, and HER2 status should be established through appropriate testing.

Q10. Is VIVITRA available for international pharmaceutical supply?

Availability and export are subject to product availability, destination-country regulations, prescription requirements, and applicable import laws.

11. Substitutes for VIVITRA 150MG Injection

Because VIVITRA contains trastuzumab, potential alternatives may include other trastuzumab brands or biosimilar products, depending on the country and regulatory approval.

Examples listed by Indian pharmacy sources include:

  • Trumab 150 Injection
  • Ontramab 150mg Injection
  • Tarzed 150 Injection

These should not be considered automatically interchangeable. A doctor or pharmacist should select the appropriate trastuzumab product based on indication, formulation, regulatory status, patient factors, and treatment protocol.

12. SEO Keywords

Primary keywords:

  • VIVITRA 150MG Injection
  • Vivitra 150 mg Injection exporter
  • Vivitra 150mg supplier from India
  • Vivitra 150mg wholesale supplier
  • Trastuzumab 150mg Injection
  • Trastuzumab 150mg exporter India
  • HER2 positive cancer medicine
  • HER2 targeted therapy
  • Breast cancer injection supplier
  • Trastuzumab injection supplier

Long-tail B2B keywords:

  • Buy VIVITRA 150MG Injection from India
  • VIVITRA 150MG Injection wholesale supplier India
  • VIVITRA 150MG Injection pharmaceutical exporter
  • VIVITRA 150MG Injection supplier from Nagpur India
  • Trastuzumab 150mg Injection exporter from India
  • Genuine VIVITRA 150MG Injection supplier
  • VIVITRA 150MG Injection international pharmaceutical supplier
  • VIVITRA 150MG Injection bulk medicine supplier
  • HER2 positive breast cancer medicine exporter India
  • Trastuzumab 150mg wholesale pharmaceutical supplier
  • VIVITRA 150MG Injection supplier to USA
  • VIVITRA 150MG Injection supplier to UK
  • VIVITRA 150MG Injection supplier to Australia
  • VIVITRA 150MG Injection supplier to Singapore
  • VIVITRA 150MG Injection supplier to Canada
  • VIVITRA 150MG Injection supplier to South Korea
  • VIVITRA 150MG Injection supplier to UAE
  • Cancer medicine exporter from Nagpur India
  • Oncology medicine exporter from India
  • Pharmaceutical oncology products supplier India
Aug 22nd, 2026 12:55 PM

Keywords